We are live on ! Find out more
RPAM

Rhenman & Partners Asset Management Portfolio holdings

AUM $810M
1-Year Est. Return 30.2%
This Fund
S&P 500
This Quarter Est. Return
+18.42%
1 Year Est. Return
+30.2%
3 Year Est. Return
+116.38%
5 Year Est. Return
+153.13%
10 Year Est. Return
+962.25%
AUM
$1.07B
AUM Growth
+$166M
Cap. Flow
+$47.2M
Cap. Flow %
4.41%
Top 10 Hldgs %
29.4%
Holding
105
New
13
Increased
43
Reduced
32
Closed
11

Top Buys

Rank Stock Value
1
REGN icon
Regeneron Pharmaceuticals
REGN
+$17.2M
2
DOCS icon
Doximity
DOCS
+$13.3M
3
AMGN icon
Amgen
AMGN
+$11.4M
4
NUVL
Nuvalent
NUVL
+$10.9M
5
VERA icon
Vera Therapeutics
VERA
+$10.3M

Top Sells

Rank Stock Value
1
EXAS
Exact Sciences
EXAS
+$19M
2
CAH icon
Cardinal Health
CAH
+$14.8M
3
ABT icon
Abbott
ABT
+$13.2M
4
CYTK icon
Cytokinetics
CYTK
+$13.1M
5
IONS icon
Ionis Pharmaceuticals
IONS
+$11.4M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BIIB icon
26
Biogen
BIIB
$30.6B
$16.3M 1.52%
92,350
+37,350
+68% +$6.1M
VRTX icon
27
Vertex Pharmaceuticals
VRTX
$133B
$15.5M 1.45%
34,255
-12,700
-27% -$5.47M
EHC icon
28
Encompass Health
EHC
$12.5B
$15.5M 1.45%
146,263
+26,863
+22% +$3.11M
GILD icon
29
Gilead Sciences
GILD
$165B
$15.5M 1.45%
126,150
+46,000
+57% +$5.59M
ALGN icon
30
Align Technology
ALGN
$12.5B
$15.5M 1.44%
99,000
+16,000
+19% +$2.29M
THC icon
31
Tenet Healthcare
THC
$20.9B
$15.2M 1.42%
76,504
+18,075
+31% +$3.65M
BMRN icon
32
BioMarin Pharmaceuticals
BMRN
$13.3B
$12.8M 1.19%
215,000
+28,350
+15% +$1.54M
JAZZ icon
33
Jazz Pharmaceuticals
JAZZ
$16.7B
$12.6M 1.18%
74,030
-21,000
-22% -$3.22M
IONS icon
34
Ionis Pharmaceuticals
IONS
$9.46B
$12.5M 1.17%
158,500
-151,500
-49% -$11.4M
AMGN icon
35
Amgen
AMGN
$226B
$11.8M 1.1%
+36,000
New +$11.4M
LIVN icon
36
LivaNova
LIVN
$4.21B
$11.7M 1.09%
190,000
+137,000
+258% +$7.83M
MDGL icon
37
Madrigal Pharmaceuticals
MDGL
$11.9B
$11.4M 1.06%
19,550
+1,300
+7% +$664K
CI icon
38
Cigna
CI
$73.6B
$10.6M 0.99%
38,650
-7,850
-17% -$2.2M
GPCR icon
39
Structure Therapeutics
GPCR
$3.82B
$10.3M 0.96%
147,600
-32,500
-18% -$1.33M
SNDX icon
40
Syndax Pharmaceuticals
SNDX
$1.82B
$10.2M 0.96%
487,000
-87,000
-15% -$1.52M
NRIX icon
41
Nurix Therapeutics
NRIX
$2.69B
$10.2M 0.95%
537,500
+190,000
+55% +$2.73M
PNTG icon
42
Pennant Group
PNTG
$1.38B
$10.1M 0.94%
+357,346
New +$9.51M
ADPT icon
43
Adaptive Biotechnologies
ADPT
$4.05B
$9.83M 0.92%
605,000
+110,000
+22% +$1.8M
PEN icon
44
Penumbra
PEN
$12.8B
$9.79M 0.92%
31,500
+11,000
+54% +$3.04M
ARWR icon
45
Arrowhead Research
ARWR
$12.5B
$9.59M 0.9%
+144,500
New +$7.08M
APLS
46
DELISTED
Apellis Pharmaceuticals
APLS
$9.41M 0.88%
374,450
+142,200
+61% +$3.34M
NTRA icon
47
Natera
NTRA
$45.9B
$9.28M 0.87%
40,500
+9,500
+31% +$1.98M
KURA icon
48
Kura Oncology
KURA
$874M
$9.06M 0.85%
872,000
+382,000
+78% +$4.01M
ACLX
49
DELISTED
Arcellx
ACLX
$8.7M 0.81%
133,500
+68,250
+105% +$5.44M
IDYA icon
50
IDEAYA Biosciences
IDYA
$3.54B
$8.64M 0.81%
+250,000
New +$7.97M
1
2
3 4 5

Similar funds

ACM
Ashford Capital Management Wilmington, Delaware $809M AUM 35.1% 1-Year Est. Return
AR
Advisory Research Chicago, Illinois $813M AUM 36.71% 1-Year Est. Return
KCP
Kera Capital Partners San Jose, California $815M AUM 46.39% 1-Year Est. Return
BCM
Brigade Capital Management New York $806M AUM 20.71% 1-Year Est. Return
RIM
Redwood Investment Management Scottsdale, Arizona $805M AUM 15.01% 1-Year Est. Return
GCM
Glendon Capital Management Santa Monica, California $805M AUM 17.91% 1-Year Est. Return
CL
CVFG LLC Shelbyville, Indiana $804M AUM 27.61% 1-Year Est. Return
AF
Ally Financial Detroit, Michigan $804M AUM 0.18% 1-Year Est. Return

Rhenman & Partners Asset Management's Q4 2025 Portfolio in Review

As of Q4 2025, Rhenman & Partners Asset Management held 105 positions worth $1.07B, up 18% from $904M the previous quarter. Its ten largest holdings account for 29% of the portfolio.

Rhenman & Partners Asset Management deployed $47.2M of net new capital in Q4 2025, opening 13 new positions and adding to 43 existing holdings. Its largest new stake was Amgen: 36,000 shares worth $11.8M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was Cytokinetics, an estimated $13.1M trimmed.

  • Rhenman & Partners Asset Management's largest Q4 2025 buy was Amgen: 36,000 shares worth $11.8M.
  • Rhenman & Partners Asset Management added most to Regeneron Pharmaceuticals in Q4 2025, an estimated $17.2M increase.
  • Rhenman & Partners Asset Management's biggest Q4 2025 reduction was Cytokinetics, cutting an estimated $13.1M.
  • Rhenman & Partners Asset Management fully exited Exact Sciences in Q4 2025, selling an estimated $19M.
  • Rhenman & Partners Asset Management's ten largest holdings make up 29% of its $1.07B portfolio in Q4 2025.
  • Rhenman & Partners Asset Management opened 13 new positions and closed 11 in Q4 2025.
  • Rhenman & Partners Asset Management's portfolio value rose 18% quarter-over-quarter to $1.07B.

Based on Rhenman & Partners Asset Management's 13F filing for Q4 2025, filed 13 Feb 2026.